U.S. Food and Drug Administration lifts partial clinical hold on lacutamab TELLOMAK trial in advanced T-cell lymphomas
June 24, 2020Innate Pharma to re-activate TELLOMAK trial in the US New GMP-certified batch has been successfully manufactured Conference call to be held today on the lacutamab clinical trial program Innate Pharma...Outcome of Annual General Meeting of May 19, 2020
May 20, 2020Pascale Boissel appointed new member of Innate’s Supervisory Board Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announces the results of...Innate Pharma to present new efficacy data for monalizumab in combination with cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program
May 14, 2020Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation Innate Pharma SA (Euronext...Innate Pharma First Quarter 2020 Report
May 12, 2020Cash, cash equivalents and financial assets of the Company amounted to €206.9 million* First patient dosed in avdoralimab (anti-C5aR) Phase II clinical trial in COVID-19 patients with severe...Number of shares and voting rights of Innate Pharma as at May 1, 2020
May 6, 2020Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma...First patient dosed in avdoralimab Phase II clinical trial in COVID-19 patients with severe pneumonia
April 28, 2020Initial translational analysis, EXPLORE, showed overexpression of C5a/C5aR pathway in patients with severe COVID-19 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate...
